FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Commercial · sales Supplies Wegovy in Korea, co-promotes it with Chong Kun Dang and has started Korean Phase 3 trials of a next-generation obesity drug.

  • The MFDS approved two Phase 3 trials of amycretin. Source
  • Signed a Korean co-promotion agreement for Wegovy with Chong Kun Dang. Source

Roles often seen at this stageSales & marketing · Medical & MSL · Clinical & PV

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Novo Nordisk Pharma Korea

The Korean arm of Denmark's Novo Nordisk, supplying medicines such as the obesity drug Wegovy in Korea and running Korean clinical trials.

Wegovy

Marketed

A once-weekly obesity injection approved by Korea's MFDS in April 2023 and launched in Korea in October 2024; it ranked first in Korean prescription-drug sales in Q2 2025.

Amycretin (NNC0487-0111)

Phase 3

Next-generation obesity candidate; in February 2026 the MFDS approved two Phase 3 trials (AMAZE 2 and HF-POLARIS) that include Korean patients.

Completion reported

Two amycretin Phase 3 trials were approved by the MFDS, with 215 Korean patients taking part.

Completion reported

Signed a Korean co-promotion agreement for Wegovy with Chong Kun Dang, with joint sales to hospitals and clinics from October 2025.

Completion reported

Introduced tiered pricing for Wegovy in Korea, lowering prices by up to 40% depending on dose.

Official role guide

Novo Nordisk Pharma Korea careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 4

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 한국 노보노디스크, 비만치료제 '위고비' 국내 출시 ↗바이오스펙테이터 · Published 2024-10-16 · Sources checked 2026-11-18 · Original unavailable
  2. 위고비 만든 노보노디스크, 차세대 비만약 한국 임상 본격화 ↗데일리팜 · Published 2026-02-27 · Sources checked 2026-11-18 · Original unavailable
  3. 종근당-노보노디스크, '위고비' 공동 판매 계약 ↗청년의사 · Published 2025-09-18 · Sources checked 2026-11-18 · Original unavailable
  4. 비만치료제 '위고비' 가격 40% 인하…"한국만 적용" ↗ZDNet Korea · Published 2025-08-13 · Sources checked 2026-11-18 · Original unavailable